RNXT · RenovoRx, Inc.
Market Cap
$74.91M
Shares
45.13M
Volume · Oct 2
269.37K
Avg daily vol (3M)
745.21K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.58
Open$1.57
Day$1.55–1.61
52W close$0.73–2.52
Avg vol 30d1.2M
Short int674K · 1.5% float · 1.0d
Short vol43%
Last earningsAug 12, 2026
DataAug 2021–Oct 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Nov 11, 2026
Est · unconfirmed
· in 5 wks
filed Aug 13, 2026
call held Aug 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+24.4%
Trailing year
Short interest
1.5%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+48%
above
Price vs 50-day avg
+6%
above
RSI (14)
47
neutral
MACD trend
Negative
52-week position
47%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−33%
trailing
6-month return
+55%
trailing
YTD return
+88%
this year
Relative strength
+43%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Distributing
-10% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.49% of float · ▲ +55.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
28 holders — mid 3-yr range
Squeeze score
47
elevated · 0–100
Fundamentals
Revenue growth
+2512%
Y/Y
Gross margin
71%
contracting
EPS growth
+20%
Y/Y
Free cash flow
$-11.0M
Quant / Vol
risk profile
Volatility
87%
annualized · 1-yr
Max drawdown
−45%
past year
ATR
9.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 12, 2026
Full year 2026 revenue
· full year 2026
Initiated
$3.75M – $4.25M
prior FY $1.12M
midpoint +256.2% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+48%
Bullish
Price vs 50-day avg
+6%
Bullish
RSI (14)
47
Neutral
MACD trend
Negative
Bearish
52-week position
47%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Distributing
-10% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.49% of float · ▲ +55.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
28 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $2 · 47%
Range high $3
vs 200-day avg +48%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| active commercial cancer centers | 21 | the second quarter of 2026 filing | — |
| clinical trial sites under Phase III TIGeR-PaC study that have previously utilized RenovoCath | 15 | second quarter of 2026 filing | — |
| total commercial funnel (active plus evaluation centers) | 63 | the second quarter of 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RNXT
this stock
RenovoRx, Inc.
|
$74.91M | +88.1% | +2511.6% | — | 1.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RNXT | -4.8% | -33.3% | +54.9% | +1.3% | +88.1% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -4.6% | -32.9% | +42.7% | +0.4% | +75.2% |